# Davern Capital Partners, LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 2003147. Source: https://holderbook.com/funds/2003147-davern-capital-partners-lp/

- Reported value: $586.5M
- Positions: 15
- Weight of the ten largest: 86.8%
- Filed: 2026-08-13

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| BIONTECH SE | [BNTX](https://holderbook.com/stocks/BNTX/) | $70.2M | 754,550 | 12.0% | 3 |
| ROIVANT SCIENCES LTD | [ROIV](https://holderbook.com/stocks/ROIV/) | $68.4M | 1,932,904 | 11.7% | 3 |
| ROYALTY PHARMA PLC | [RPRX](https://holderbook.com/stocks/RPRX/) | $64.8M | 1,155,809 | 11.0% | 3 |
| IONIS PHARMACEUTICALS INC | [IONS](https://holderbook.com/stocks/IONS/) | $63.3M | 798,709 | 10.8% | 3 |
| INSMED INC | [INSM](https://holderbook.com/stocks/INSM/) | $59.7M | 559,824 | 10.2% | 2 |
| REGENERON PHARMACEUTICALS | [REGN](https://holderbook.com/stocks/REGN/) | $57.8M | 92,640 | 9.8% | 3 |
| LEGEND BIOTECH CORP | [LEGN](https://holderbook.com/stocks/LEGN/) | $34.4M | 1,191,522 | 5.9% | 3 |
| ALNYLAM PHARMACEUTICALS INC | [ALNY](https://holderbook.com/stocks/ALNY/) | $34.0M | 113,085 | 5.8% | 1 |
| NATERA INC | [NTRA](https://holderbook.com/stocks/NTRA/) | $32.3M | 118,975 | 5.5% | 3 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $23.9M | 446,059 | 4.1% | 2 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $23.2M | 858,753 | 4.0% | 3 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $21.4M | 498,832 | 3.6% | 1 |
| GENERATE BIOMEDICINES INC | [GENB](https://holderbook.com/stocks/GENB/) | $13.9M | 824,679 | 2.4% | 2 |
| PROCEPT BIOROBOTICS CORP | [PRCT](https://holderbook.com/stocks/PRCT/) | $10.5M | 464,920 | 1.8% | 2 |
| AVALO THERAPEUTICS INC | [AVTX](https://holderbook.com/stocks/AVTX/) | $8.7M | 468,666 | 1.5% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +9.1% | +14.8% | -5.7% | 100% |
| Q1 2026 | +1.3% | -4.6% | +5.9% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $586.5M | 15 |
| Q1 2026 | $364.5M | 17 |
| Q4 2025 | $309.3M | 14 |